INSIGHTEC, a commercial-stage medical technology company, announced it has raised Series F funding of up to $150 million at a post-money valuation of $1.3 billion. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, is leading the round and has committed to invest $100 million at an initial closing to follow shareholder approval. This is KDT’s second direct investment in INSIGHTEC.
The company will utilise the funds to support its research to evaluate focused ultrasound to treat certain movement disorders in patients suffering from essential tremor and tremor-dominant Parkinson’s disease who have not responded to medications, and other disorders.
“Our partnership with KDT and other investors is helping to fuel our momentum as a rapidly growing number of medical institutions adopt our focused ultrasound technology,” said Maurice R. Ferré, MD, INSIGHTEC’s Chief Executive Officer and Chairman of the Board. “This new investment demonstrates our investors’ commitment to help drive the next generation of focused ultrasound.”
“INSIGHTEC’s focused ultrasound technology is disrupting the way surgery has been performed for generations,” commented Chase Koch, President of Koch Disruptive Technologies. “KDT is focused on empowering innovative companies and helping them realize their potential to improve the lives of millions of people. “
INSIGHTEC is a global medical technology innovator transforming patient lives through incisionless brain surgery using focused ultrasound guided by MR imaging. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Shanghai and Tokyo.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.